Neuralink's first brain implant enables patient to control mouse by thinking

Neuralink now aims to make patient capable of performing as many mouse click as possible
A representational image. — Unsplash
A representational image. — Unsplash

Implantable brain chips producing company Neuralink's first chip implant in a human brain begins yielding positive positive results as Elon Musk said on Monday the the patient is able to control a computer mouse just with his brain.

The CEO of Neuralink, SpaceX, Tesla, and X (formerly Twitter)said in a Space event on Twitter on his social media platform, "Progress is good, and the patient seems to have made a full recovery, with no ill effects that we are aware of. Patient is able to move a mouse around the screen by just thinking."

Citing Musk, Reuters reported that after having succeeded in implanting a brain chip on its first human patient, the company now aims to make the patient capable of performing as many mouse click as possible.

Read more: Lockbit cybercrime gang disrupted by international law enforcement operation

Valued at about $5 billion as of last year, Neuralink's first ever implant was planned and executed a month earlier, after it was receiving approval in September to conduct human trials.

Musk said that the process involves a robot which surgically positions a brain-computer interface implant in a region of the brain that controls the intention to move, adding that the initial goal of the implant is to make people control computer cursor on a screen, and keyboard through their thoughts only.

Expressing devotion and staunch dedication towards Neuralink projects, Tesla boss said the company would provide rapid implants of its chips that would treat people with conditions like obesity, autism, depression, and schizophrenia.

As it was fined last month for contravening US Department of Transportation regulations devised for the movement of hazardous materials, the company has been receiving calls to undergo inspections pertaining to the safety protocols it follows.